abstract |
Described herein are methods for selecting cancer patients for treatment with a combination ntherapy comprising entinostat and a second therapeutic agent. In particular, methods are nprovided for the exam-ination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., nthose which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the nsetting of entinostat combination therapies. |